Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FOXO TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FOXO TECHNOLOGIES's regulatory disclosures and financial reporting.
FOXO Technologies Inc., through its subsidiary Vector BioSource, Inc., agreed to acquire certain assets and assume certain liabilities tied to four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. The asset purchase agreement provides for $3,500,000 in cash at closing plus a contingent earn-out of up to $1,000,000 in cash.
The full earn-out becomes payable if the acquired business generates EBITDA of $1,500,000 or more in any single calendar year during 2026–2028. Closing is subject to customary conditions and to Vector obtaining its own FDA license, CLIA certifications in relevant states, and a Miami waste-management permit. Either party may terminate if closing has not occurred within nine months after July 22, 2026, and the company currently anticipates closing in the third or fourth quarter of 2026.
FOXO Technologies provided a mid-year update highlighting strong early-2026 operating momentum and capital-structure changes. Net revenues were approximately $5.1 million for the three months ended March 31, 2026, compared with $3.2 million a year earlier, while loss from operations narrowed to $0.3 million from $1.5 million.
The company completed a 1:3,000 reverse stock split, exchanged about $7.8 million in stated value of Series A Convertible Preferred Stock into non-convertible debt, and established a new epigenetics licensing arrangement that pays a 3% royalty on net revenues, capped at $1.3 million. Myrtle Recovery’s Oneida facility is operating near full capacity with an average daily census of 27.6 (about 92% occupancy), up from 7.4 in 2024, and annualized 2026 admissions of about 700. Big South Fork Medical Center remains the main revenue driver, projected to increase inpatient and swing bed admissions in 2026. The Vector BioSource unit is pursuing a potential acquisition that, if completed, is expected to add more than $10 million of annual revenue. FOXO is also exploring an uplisting of its Class A common stock to NYSE American or another exchange and intends to use its dividend-bearing Series E Preferred Stock for future acquisitions and capital raising.
FOXO Technologies Inc. has implemented a 1-for-3,000 reverse stock split of its Class A common stock. Every 3,000 pre-split shares have been combined into one share, with no change to the $0.0001 par value per share.
The reverse split became effective at 4:01 p.m. Eastern Time on June 30, 2026, and the stock began trading on a split-adjusted basis on July 1, 2026 under a new CUSIP (351471602) and temporary symbol FOXOD. No fractional shares are issued; any fractional amounts are rounded up to the nearest whole share.
The company states the split is intended to increase the per-share price to support a potential quotation on OTCQB, which requires a sustained price of at least $0.01, and could also be a step toward a potential uplisting to a recognized exchange if listing requirements are met. Outstanding stock options, warrants, and equity incentive plans will be proportionately adjusted, and FOXO does not expect any impact on current or future business operations.
FOXO Technologies Inc. states its Board and a Majority Shareholder approved a reverse stock split range of one-for-one thousand (1:1,000) to one-for-ten thousand (1:10,000), to be effected at the Board’s sole discretion prior to November 30, 2026. The action was authorized by written consent dated May 18, 2026 and will be completed by filing a Certificate of Amendment with the Delaware Secretary of State.
The Information Statement discloses 4,261,663,700 shares of Common Stock outstanding as of the Record Date and shows estimated post-split outstanding shares between 4,261,664 (1:1,000) and 426,166 (1:10,000). The filing explains the Board’s rationale is to increase per-share trading price for potential OTCQB quotation or an exchange listing, notes prior FINRA processing issues have been addressed, and describes fractional-share treatment (round up).
FOXO Technologies Inc. entered into a Strategic Technology License Agreement with founder Jon R. Sabes and LongevityFP Technologies, LLC. The deal grants LongevityFP Technologies an exclusive worldwide license to commercialize FOXO’s epigenetics intellectual property, including two issued U.S. patents, datasets, and machine learning models.
LongevityFP Technologies will pay FOXO a royalty equal to 3% of net revenues from the licensed technology, capped at $1.3 million, and receives a ten-year exclusive option to acquire majority ownership of FOXO Labs, Inc. Depending on the option structure, FOXO would retain a 40% equity interest in the resulting epigenetics enterprise. The agreement includes mutual releases and resolves prior matters between the parties.
FOXO Technologies Inc. reached a settlement with J.H. Darbie & Co. to resolve obligations under several prior agreements. The company will issue 400 shares of Series D Cumulative Convertible Redeemable Preferred Stock and pay $175,000 in seven monthly installments of $25,000 from May through December 2026. If FOXO misses payments, the unpaid balance may be converted into Class A common shares at 90% of the 20‑day volume‑weighted average price, capped by a 4.99% beneficial ownership limit. Separately, a majority stockholder controlled by the CEO, holding about 95.56% of voting rights as of May 18, 2026, approved a reverse stock split by written consent. The reverse split will become effective no earlier than 20 days after mailing a definitive Schedule 14C and remains subject to FINRA approval.
FOXO Technologies Inc. is informing stockholders that its Board and a majority shareholder approved a reverse stock split to amend the Certificate of Incorporation, allowing a split ratio in the range 1:1,000 to 1:10,000, with the Board to select the final ratio and effect the split, if at all, prior to November 30, 2026. The Board and the Majority Shareholder provided written consents on May 13, 2026 and May 18, 2026, respectively, and the Reverse Split will become effective upon filing a Certificate of Amendment with the Delaware Secretary of State. As of the record date the Company had 4,261,663,700 shares of Common Stock outstanding and estimates post-split outstanding shares would range from approximately 4,261,664 (1:1,000) to 426,166 (1:10,000). The filing explains FINRA interactions that prevented a prior split, recent exchanges of Series A Preferred Stock for notes, fractional-share treatment (rounded up), and that no dissenters’ appraisal rights will be provided.
FOXO Technologies Inc. entered into two Exchange Agreements with institutional investors to restructure its Series A Cumulative Convertible Redeemable Preferred Stock into senior unsecured non-convertible promissory notes. Investor 1 exchanged 2,467.98834 Series A shares with a stated value of $2,467,988.34 for an equal principal amount note, and Investor 2 exchanged 5,307.09694 Series A shares with a stated value of $5,307,096.94 for a matching principal amount note.
The exchanged preferred shares are cancelled, and the investors no longer hold instruments with conversion rights to FOXO equity. Each Senior Note is non-interest bearing, unsecured, and matures on the earlier of May 12, 2027 or the occurrence of an Event of Default, with an 18% per annum default interest rate. The company agrees not to incur indebtedness senior to these notes, repayment is to occur upon completion of a public offering or up-listing to a recognized stock exchange, and proceeds are earmarked for working capital purposes.
FOXO Technologies Inc. reports Q1 2026 results with net revenues of $5.17 million, up from $3.17 million a year earlier, mainly from its healthcare and life science services businesses. Despite higher revenue, FOXO recorded a net loss to common stockholders of $1.74 million.
The company ended March 31, 2026 with $65,896 in cash and a working capital deficit of $27.1 million, and it carries $8.61 million of current debt. Management discloses that these conditions and ongoing losses raise substantial doubt about FOXO’s ability to continue as a going concern absent additional financing and improved cash flow.
FOXO Technologies Inc. is amending its charter to increase its authorized capital to 25,020,000,000 shares. This will consist of 25,000,000,000 shares of Class A Common Stock and 20,000,000 shares of Preferred Stock, each with a par value of $0.0001 per share.
The Certificate of Amendment was authorized and approved by stockholders and adopted in accordance with Sections 212 and 242 of the Delaware General Corporation Law. It is scheduled to become effective upon filing with the Delaware Secretary of State on May 3, 2026.